Table 1.
Demographics and baseline characteristics of the study groups
| Parameter | 5 mg group [n = 25] | 3 mg group [n = 25] | p value |
|---|---|---|---|
| Age, years [mean ± SD] | 43.2 ± 12.7 | 49.3 ± 8.0 | 0.048a,e |
| Male [n (%)] | 13 (52) | 11 (44) | 0.571b |
| BMI, kg/m2 [mean ± SD] | 30.6 ± 5.9 | 27.8 ± 3.7 | 0.061a |
| Smoking status [n (%)] | 6 (24) | 5 (20) | 0.733b |
| INR [mean ± SD] | 1.1 ± 0.1 | 1.1 ± 0.1 | 0.279a |
| Serum creatinine, mg/dL [median (IQR)] | 1.10 (0.90–1.16) | 0.83 (0.79–0.94) | 0.001c,e |
| Platelet count, ×1000/μL [mean ± SD] | 381 ± 66 | 390 ± 59 | 0.613a |
| ALT, IU/L [mean ± SD] | 23.7 ± 5.1 | 19.0 ± 5.0 | 0.052a |
| AST, IU/L [mean ± SD] | 21.8 ± 5.4 | 20.1 ± 3.9 | 0.090a |
| Serum albumin, g/dL [mean ± SD] | 4.1 ± 0.4 | 4.2 ± 0.5 | 0.608a |
| Number of patient comorbidities [median (IQR)] | 1 (0–1) | 1 (0–1) | 0.142c |
| Comorbid diseases [n (%)] | |||
| Diabetes mellitus | 7 (28) | 7 (28) | 1.00b |
| Hypertension | 2 (8) | 5 (20) | 0.417 |
| Rheumatic heart disease | 4 (16) | 4 (16) | 1.00b |
| Atrial fibrillation | 2 (8) | 2 (8) | d |
| Hyperlipidemia | 0 (0) | 2 (8) | d |
| Hypothyroidism | 1 (4) | 2 (8) | d |
| Medications [n (%)] | |||
| Amiodarone | 7 (28) | 4 (16) | 0.306b |
| Cefazolin | 23 (92) | 23 (92) | 1.00b |
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, INR international normalized ratio, IQR interquartile range, SD standard deviation
aIndependent t test
bChi-square test
cMann–Whitney test
dNo p value given because of the small number of cases within groups
ep value < 0.05: significant